Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59 %, with the overall attrition rate for breast cancer standing at 85 %.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
The breast cancer Southeast Asian market will be valued at $ 2.7 billion in 2022, growing from $ 942.3m in 2015 at a CAGR of 16.2 %.
- Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?
Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.
- How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
Download sample Copy of This Report at: http:// www. radiantinsights. com / research / breast-cancer-therapeutics-in-southeastasia-markets-to-2022 / request-sample
- What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
- How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
- How will the potential launch of biosimilars influence each country?
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers will influence the market over the forecast period.- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?- What factors are most likely to drive the market in these countries?
Reasons to buy This report will allow you to-
Follow Us: